Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer.
Takehara K, Matsumoto T, Hamanishi J, Hasegawa K, Matsuura M, Miura K, Nagao S, Nakai H, Tanaka N, Tokunaga H, Ushijima K, Watari H, Yokoyama Y, Kase Y, Sumino S, Suri A, Itamochi H, Takeshima N. Takehara K, et al. Among authors: itamochi h. J Gynecol Oncol. 2021 Mar;32(2):e21. doi: 10.3802/jgo.2021.32.e21. Epub 2021 Jan 6. J Gynecol Oncol. 2021. PMID: 33470063 Free PMC article. Clinical Trial.
Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I; Sankai Gynecology Study Group (SGSG). Miyagi Y, et al. Among authors: itamochi h. Gynecol Oncol. 2005 Dec;99(3):591-6. doi: 10.1016/j.ygyno.2005.06.055. Epub 2005 Aug 10. Gynecol Oncol. 2005. PMID: 16095677 Clinical Trial.
Bevacizumab and ovarian cancer.
Sato S, Itamochi H. Sato S, et al. Among authors: itamochi h. Curr Opin Obstet Gynecol. 2012 Feb;24(1):8-13. doi: 10.1097/GCO.0b013e32834daeed. Curr Opin Obstet Gynecol. 2012. PMID: 22123222 Review.
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K, Tsunoda T, Shigemizu D, Fujiwara H, Hatae M, Fujiwara H, Masuzaki H, Katabuchi H, Kawakami Y, Okamoto A, Nogawa T, Matsumura N, Udagawa Y, Saito T, Itamochi H, Takano M, Miyagi E, Sudo T, Ushijima K, Iwase H, Seki H, Terao Y, Enomoto T, Mikami M, Akazawa K, Tsuda H, Moriya T, Tajima A, Inoue I, Tanaka K; Japanese Serous Ovarian Cancer Study Group. Yoshihara K, et al. Among authors: itamochi h. Clin Cancer Res. 2012 Mar 1;18(5):1374-85. doi: 10.1158/1078-0432.CCR-11-2725. Epub 2012 Jan 12. Clin Cancer Res. 2012. PMID: 22241791
Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.
Oshita T, Itamochi H, Nishimura R, Numa F, Takehara K, Hiura M, Tanimoto H, Noma J, Hayase R, Murakami A, Fujimoto H, Kanamori Y, Kitada F, Shitsukawa K, Nagaji M, Minagawa Y, Fujiwara M, Kigawa J. Oshita T, et al. Among authors: itamochi h. Int J Clin Oncol. 2013 Dec;18(6):1107-13. doi: 10.1007/s10147-012-0483-8. Epub 2012 Oct 17. Int J Clin Oncol. 2013. PMID: 23073623
Predicting time to ovarian carcinoma recurrence using protein markers.
Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network; Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. Yang JY, et al. Among authors: itamochi h. J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15. J Clin Invest. 2013. PMID: 23945238 Free PMC article.
140 results